What's in Forest Laboratories's pipeline?

Forest Laboratories has 5 drugs in our index: 3 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Forest Laboratories's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/forest-laboratories.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Forest Laboratories — Portfolio Competitive Intelligence Brief

Forest Laboratories pipeline: 3 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Omeprazole, amoxicillin, clarithromycin	Omeprazole, amoxicillin, clarithromycin	marketed
Ceftriaxone plus vancomycin	Ceftriaxone plus vancomycin	marketed
Zenpep	Zenpep	marketed	Other
Vilazadone	Vilazadone	phase 3	Other
Cellegesic	Cellegesic	phase 3	Other

Therapeutic area mix

Other · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Forest Laboratories:

Cite this brief

Drug Landscape (2026). Forest Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/forest-laboratories. Accessed 2026-05-13.